Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
MET-233i, a monthly dosing, ultra-long acting, subcutaneously injectable amylin analog candidate being evaluated as monotherapy and in combination with MET-097i in a Phase I trial
The Protein First Rule: Because you will be eating less, every bite must count
At 12 months, there were no statistically significant differences between groups initially assigned to placebo or to treatment
Careful consideration of patient selection criteria and possible side effects, such as gastrointestinal discomfort and hypoglycemia, will be important when using GLP-1RAs for the treatment of IIH
US$ 26.40
US$ 27.27
US$ 20.44
US$ 21.00
US$ 21.39
US$ 23.13
US$ 24.46
US$ 20.99
US$ 22.96
US$ 22.17
US$ 29.62
